Prospective study of 6 newly Dx RA pts starting MTX shows MTX causes a decline in T follicular helper (Tfh) cells and plasmablasts (@ wk 3 before clin response), selectively in responders but not nonresponders. MTX shifts cellular & gene expression towards a more physiological https://t.co/scmfAAE9XA

#TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/h0oe3WksK1

EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases The 2026 EULAR vaccination recommendations, presented by Victoria Furer, were developed by a multinational 25-member task force that include rheumatologists, an https://t.co/L5XRcIxl5s

Is there a path to precision medicine in #RA? Theres a substantial unmet need. Immunoengineering is possible thru nanotechnological delivery vectors, cellular therapeutics, & biomaterial scaffolds, with compelling preclinical and early clinical support. https://t.co/gL56EOlt7p https://t.co/31IRNXckym

RHEUM SURVEY> When treating NON-RENAL lupus, is a drug with a "lupus nephritis indication" more likely to be used? Answer here >> https://t.co/1KridYM9n8 https://t.co/WiBhdKRxik

Throughout Gout Campaign Month, RheumNow is bringing together internationally recognized experts to explore the Systemic Burden of Gout through Rx Updates, QD Clinic case discussions, and expert Vlogs designed for practicing rheumatologists. New educational content will release https://t.co/ZOQQuZinQd

Bundibugyo virus disease (BVD) outbreak in the Congo in 2026. BV is an orthoebolavirus (not Ebola virus) species. Of the 2351 reported, 505 (22%)confirmed by PCR & 19% died. Sxs: Most 20-39 yrs, F>M, Fever (74%), GI & diarrhea (67%), anorexia, Abd pain (37%). HA (42%), SOB (34%), https://t.co/yYSmPjuiZW

Where are we with Biomarkers in Rheumatoid Arthritis? Biomarker interest has grown considerably in the last 2 decades, owing to advances in genetics, imaging, protein, and multiomics. Despite these advances, biomarkers as the predictive holy grail of RA therapeutics and https://t.co/ggoWx8yumZ

B cell Targeting in SLE Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest. https://t.co/wGaZPnXfID https://t.co/a0fNvdcrbQ

RHEUM SURVEY> Do you prefer a lupus drug if it has a lupus nephritis indication (when your treating non-renal SLE)? Answer here >> https://t.co/1KridYM9n8 https://t.co/zIqNB5Mc0O

NEJM on anti-CD19 CAR-T cell therapy in B cell lymphoma - 38 pts w/ refractory NHL (24 lg B-cell, 1414 follicular lymphoma) Rx w/ CTL019. 10-yr survival = 32% w/ large B-cell & 47w/ follicular lymphoma; Persistent neutropenia 5%, & 2nd primary cancer seen in 21%. B-cell aplasia https://t.co/CPKvunGZxl

Redefining axial spondyloarthritis An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need." https://t.co/C1Kei8AU3h https://t.co/lspQYyEFHa